利妥昔单抗优化天疱疮管理及短期复发预测因素
这项法国多中心队列研究评估了天疱疮患者在接受利妥昔单抗方案达到完全缓解后,若第3个月存在复发预测因素(PDAI≥45、抗DSG1>20 IU/mL和/或抗DSG3>130 IU/mL),在第6个月追加一次利妥昔单抗输注的效果。结果显示,有预测因素并接受追加治疗的患者无复发,总体12个月无激素完全缓解率达82.7%。
要点
- 第3个月PDAI≥45、抗DSG1>20 IU/mL或抗DSG3>130 IU/mL可预测短期复发。
- 对有预测因素且第6个月完全缓解者追加利妥昔单抗,可降低复发率。
- 追加治疗的需治疗人数(NNT)为3.6(95%CI 1.6-46.5)。
核心结论
- 使用基线PDAI评分、抗DSG1和/或抗DSG3抗体等预测因素启动追加利妥昔单抗的抢先治疗,可能降低短期复发率。
研究设计与样本
- 法国多中心队列研究,2018年9月至2023年6月,纳入87例新诊断天疱疮患者。
主要发现
- 第6个月77例(88.5%)达到完全缓解,其中30例(39.0%)有至少1个复发预测因素并接受追加输注,47例(61.0%)无预测因素未追加。
- 有预测因素者无复发,无预测因素者2例复发,总体复发率2.6%,NNT为3.6(95%CI 1.6-46.5)。
- 第12个月,第6个月达到完全缓解的患者中72/77(93.5%)实现至少2个月无激素完全缓解,全研究人群为72/87(82.7%)。
- 5例患者报告8次严重不良事件,无死亡。
关键数值与推荐
- 复发预测因素:PDAI评分≥45、抗DSG1抗体>20 IU/mL和/或抗DSG3抗体>130 IU/mL。
- 第6个月完全缓解且有至少1个预测因素者接受追加利妥昔单抗输注。
- 第6个月持续疾病活动者接受利妥昔单抗2000 mg再治疗。
临床怎么用
- 对利妥昔单抗治疗后第3个月存在复发预测因素的天疱疮患者,可考虑在第6个月追加一次利妥昔单抗以预防短期复发。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Rituximab is approved for the treatment of moderate to severe pemphigus. However, 20% of patients in the RITUX 3 trial relapsed within the first year of treatment. OBJECTIVE: To assess the outcome of an additional rituximab infusion at month 6 in patients with pemphigus who were in complete remission (CR) after rituximab regimen but had 1 or more predictors of relapse at month 3. DESIGN, SETTINGS, AND PARTICIPANTS: This multicenter cohort study was conducted in France from September 2018 to June 2023 to assess patients with newly diagnosed pemphigus who were in CR after treatment with the RITUX 3 regimen but had predictors of relapse at month 3. Relapse factors were a Pemphigus Disease Area Index (PDAI) score of 45 or higher, desmoglein 1 (DSG1) antibodies greater than 20 IU/mL, and/or DSG3 antibodies greater than 130 IU/mL. EXPOSURE: Patients in CR at month 6 with at least 1 predictor of relapse were treated with an additional rituximab infusion at month 6. MAIN OUTCOMES AND MEASURES: Primary end point was the rate of CR without corticosteroid therapy for 2 months at month 12. Secondary end points were the rate of relapse, number of patients needing to be re-treated (NNT) with rituximab to avoid a relapse, and safety. RESULTS: The study population comprised 87 patients (44 females [50.6%] and 43 [49.4%] males), with a mean (SD [range]) age of 55.3 (15.2 [24-92]) years at pemphigus diagnosis. Of these, 64 patients (73.6%) had pemphigus vulgaris and 23 (26.4%) had pemphigus foliaceus. At month 6, CR had been achieved by 77 patients (88.5%), and 10 (11.5%) had persistent disease activity. Of the 77 patients in CR, 30 (39.0%) had at least 1 predictor of relapse and received an additional infusion of rituximab; 47 patients (61.0%) without a predictor did not. Two patients without a predictor and no patients with a predictor experienced relapse-an overall relapse rate of 2.6% and an NNT of 3.6 (95% CI, 1.6-46.5). The 10 patients (11.5%) with persistent disease activity at month 6 were re-treated with rituximab, 2000 mg. At month 12, the rate of CR without corticosteroid therapy for a minimum of 2 months was 72 of 77 (93.5%) among patients who had achieved CR at month 6, and 72 of 87 (82.7%) for the whole study population. Eight serious adverse effects were reported among 5 patients; there were no deaths. CONCLUSION AND RELEVANCE: This multicenter cohort study indicates that using predictors such as baseline PDAI score, anti-DSG1 antibodies, and/or anti-DSG3 antibodies to initiate preemptive treatment with additional rituximab may reduce the rate of short-term relapse.
引用
- Hébert V, Hamwi S, Tancrède-Bohin E, et al. Optimizing Pemphigus Management With Rituximab and Short-Term Relapse Predictors. JAMA Dermatol. 2025. PMID: 39908046. doi:10.1001/jamadermatol.2024.6130
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。